Implementation of the Centiloid Scale for the Neuraceq radiotracer [18F]Florbetaben
DOI:
https://doi.org/10.29384/rbfm.2023.v17.19849001677Keywords:
nuclear medicine; amyloid-beta radiotracer; Centiloid scale; Positron Emission TomographyAbstract
Positron emission tomography (PET) and magnetic resonance imaging (MR) are relevant modalities in studying brain aging. The deposition of beta-amyloid plaque (bA) can be assessed by PET using specific radiotracers, such as [11C]PiB or [18F]Florbetaben. The Centiloid (CL) scale was developed to reduce the variability of the processing protocol and produce a harmonized quantification of bA PET images. The study aims to present the implementation of the CL scale for the radiotracer [18F]Florbetaben at our institution. For this, we need to validate the image processing and analysis pipeline with the data available by the Global Alzheimer's Association Interactive Network (GAAIN) for the radiotracer [18F]Florbetaben and [11C]PiB. The GAAIN has PET and MR images from 10 healthy individuals (Ab negative) and 25 Ab positive individuals, including cognitively healthy elderly, individuals with mild cognitive impairment, Alzheimer's disease, and frontotemporal dementia. In the CL scale, we used the uptake values between the global cortical region (CTX), which considers the frontal, temporal, parietal, precuneus, anterior striatum, and insular cortex regions, and the WC (whole cerebellum), as the reference region. Image processing was performed using the PMOD software with the PNEURO tool. As a result, we obtained a strong correlation between [18F]Florbetaben and [11C]PiB values for the same individuals. The final equation that transforms the SUVR values of [18F]Florbetaben to the CL scale in our institution is CLFBB= 156.47 * SUVR*PIBind - 157.47. It was validated and reached the minimum values Klunk et al. (2015) required of determination coefficient R²=0.997, angular coefficient equal to 1.00, and linear coefficient equal to 1.34. We conclude that implementing the CL scale in our institution is viable, constituting an essential step for the clinical use of the scale for longitudinal follow-up of individuals in the aging process using bA radiotracers.
Downloads
References
Dartora CM, Borelli WV, Koole M, Marques da Silva AM. Cognitive Decline Assessment: A Review From Medical Imaging Perspective. Frontiers in Aging Neuroscience. 2021; 13. doi:10.3389/fnagi.2021.704661.
Schilling LP, Zimmer ER, Shin M, Leuzy A, Pascoal TA, Benedet AL, et al. Imaging Alzheimer’s disease pathophysiology with PET. Dement neuropsychol. 2016 Jun;10(2):79–90.
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ et al. The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s and Dementia 2015; 11: 1-15.e4.
Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC et al. Centiloid scaling for quantification of brain amyloid with [ 18 F]flutemetamol using multiple processing methods. EJNMMI Research 2018; 8. doi:10.1186/s13550-018-0456-7.
Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44: 2053–2059.
de Souza GS, Andrade MA, Borelli WV, Schilling LP, Matushita CS, Portuguez MW et al. Amyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale. Molecular Imaging and Biology 2021. doi:10.1007/s11307-021-01660-7.
Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. European Journal of Nuclear Medicine and Molecular Imaging 2021; 48: 302–310.
Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M et al. Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer’s Disease: A Multicenter Study. Frontiers in Neurology 2021; 11. doi:10.3389/fneur.2020.578753.
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O et al. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology. Alzheimer’s and Dementia 2019; 15: 807–816.
la Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C et al. Multisite study of the relationships between antemortem [ 11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimer’s and Dementia 2019; 15: 205–216.
Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O et al. Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. NeuroImage 2018; 183: 387–393.
Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer’s and Dementia 2018; 14: 1565–1571.
Yamao T, Miwa K, Wagatsuma K, Shigemoto Y, Sato N, Akamatsu G et al. Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer’s disease. Physica Medica 2021; 82: 249–254.
Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: A PET substudy interim analysis. Alzheimer’s Research and Therapy 2019; 11. doi:10.1186/s13195-019-0559-z.
Amadoru S, Doré V, McLean CA, Hinton F, Shepherd CE, Halliday GM et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimer’s Research and Therapy 2020; 12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Maria Rosa Alves da Silva, Giordana Salvi de Souza, Ana Maria Marques da Silva
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The submission of original articles to the Brazilian Journal of Medical Physics implies the transfer, by the authors, of the rights of print and digital publication. Copyright for published articles remains with the author, with journal rights on first publication. Authors may only use the same results in other publications by clearly indicating this journal as the original publisher. As we are an open access journal, free use of articles in educational, scientific, non-commercial applications is allowed, as long as the source is cited.
The Brazilian Journal of Medical Physics is under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
